|
1
|
Morris CD, Teot LA, Bernstein ML, Marina
N, Krailo MD, Villaluna D, Janeway KA, DuBois SG, Gorlick RG and
Randall RL: Assessment of extent of surgical resection of primary
high-grade osteosarcoma by treating institutions: A report from the
Children's Oncology Group. J Surg Oncol. 113:351–354. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grignani G, Palmerini E, Dileo P, Asaftei
SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F,
Casali PG, et al: A phase II trial of sorafenib in relapsed and
unresectable high-grade osteosarcoma after failure of standard
multimodal therapy: An Italian Sarcoma Group study. Ann Oncol.
23:508–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hugate RR, Wilkins RM, Kelly CM, Madsen W,
Hinshaw I and Camozzi AB: Intraarterial chemotherapy for extremity
osteosarcoma and MFH in adults. Clin Orthop Relat Res.
466:1292–1301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nataraj V, Batra A, Rastogi S, Khan SA,
Sharma MC, Vishnubhatla S and Bakhshi S: Developing a prognostic
model for patients with localized osteosarcoma treated with uniform
chemotherapy protocol without high dose methotrexate: A
single-center experience of 237 patients. J Surg Oncol.
112:662–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YH, Goh TS, Lee CS, Oh SO, Kim JI,
Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma:
A meta-analysis. Oncotarget. 8:8726–8737. 2017.PubMed/NCBI
|
|
6
|
Li H, Zhang K, Liu LH, Ouyang Y, Guo HB,
Zhang H, Bu J and Xiao T: MicroRNA screening identifies circulating
microRNAs as potential biomarkers for osteosarcoma. Oncol Lett.
10:1662–1668. 2015.PubMed/NCBI
|
|
7
|
Torreggiani E, Roncuzzi L, Perut F, Zini N
and Baldini N: Multimodal transfer of MDR by exosomes in human
osteosarcoma. Int J Oncol. 49:189–196. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y,
Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration,
invasion and epithelial-mesenchymal transition in osteosarcoma
cells via targeting Sirtuin 1. Oncol Rep. 34:399–406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li C, Dong J, Han Z and Zhang K:
MicroRNA-219-5p represses the proliferation, migration, and
invasion of gastric cancer cells by targeting the
LRH-1/Wnt/β-catenin signaling pathway. Oncol Res. 25:617–627. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang W, Tian Y, Jiang S, Liu S, Zhao X
and Tian D: MicroRNA-376c suppresses non-small-cell lung cancer
cell growth and invasion by targeting LRH-1-mediated Wnt signaling
pathway. Biochem Biophys Res Commun. 473:980–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bianco S, Brunelle M, Jangal M, Magnani L
and Gévry N: LRH-1 governs vital transcriptional programs in
endocrine-sensitive and -resistant breast cancer cells. Cancer Res.
74:2015–2025. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Z, Wu S, Lv S, Wang H, Wang Y and Guo
Q: Suppression of liver receptor homolog-1 by microRNA-451
represses the proliferation of osteosarcoma cells. Biochem Biophys
Res Commun. 461:450–455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xue YL, Meng XQ, Ma LJ and Yuan Z:
Plumbagin exhibits an anti-proliferative effect in human
osteosarcoma cells by downregulating FHL2 and interfering with
Wnt/β-catenin signalling. Oncol Lett. 12:1095–1100. 2016.PubMed/NCBI
|
|
14
|
London CA, Gardner HL, Mathie T, Stingle
N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM,
Williams LE, et al: Impact of toceranib/piroxicam/cyclophosphamide
maintenance therapy on outcome of dogs with appendicular
osteosarcoma following amputation and carboplatin chemotherapy: A
multi-institutional study. PLoS One. 10:e01248892015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pappo AS, Vassal G, Crowley JJ, Bolejack
V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon
AP, et al: A phase 2 trial of R1507, a monoclonal antibody to the
insulin-like growth factor-1 receptor (IGF-1R), in patients with
recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial
sarcoma, and other soft tissue sarcomas: Results of a Sarcoma
Alliance for Research Through Collaboration study. Cancer.
120:2448–2456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song BS, Seo J, Kim DH, Lim JS, Yoo JY and
Lee JA: Gemcitabine and docetaxel for the treatment of children and
adolescents with recurrent or refractory osteosarcoma: Korea Cancer
Center Hospital experience. Pediatr Blood Cancer. 61:1376–1381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lewis IJ, Nooij MA, Whelan J, Sydes MR,
Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van
Glabbeke M, et al MRC BO06 and EORTC 80931 collaborators, ;
European Osteosarcoma Intergroup, : Improvement in histologic
response but not survival in osteosarcoma patients treated with
intensified chemotherapy: A randomized phase III trial of the
European Osteosarcoma Intergroup. J Natl Cancer Inst. 99:112–128.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Q, Zhao S, Pang X and Chi B:
MicroRNA-381 suppresses cell growth and invasion by targeting the
liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep.
35:1831–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang T, Xu Z, Wang K and Wang N: Network
analysis of microRNAs and genes in human osteosarcoma. Exp Ther
Med. 10:1507–1514. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ram Kumar RM, Boro A and Fuchs B:
Involvement and clinical aspects of microRNA in osteosarcoma. Int J
Mol Sci. 17:8772016. View Article : Google Scholar :
|
|
21
|
Li Z, Zhao L and Wang Q: Overexpression of
long non-coding RNA HOTTIP increases chemoresistance of
osteosarcoma cell by activating the Wnt/β-catenin pathway. Am J
Transl Res. 8:2385–2393. 2016.PubMed/NCBI
|
|
22
|
Zhou L, An N, Jiang W, Haydon R, Cheng H,
Zhou Q, Breyer B, Feng T and He TC: Fluorescence-based functional
assay for Wnt/beta-catenin signaling activity. Biotechniques.
33:1126–1128, 1130, 1132 passim. 2002.PubMed/NCBI
|
|
23
|
Tian J, He H and Lei G: Wnt/β-catenin
pathway in bone cancers. Tumour Biol. 35:9439–9445. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reimann E, Kõks S, Ho XD, Maasalu K and
Märtson A: Whole exome sequencing of a single osteosarcoma case -
integrative analysis with whole transcriptome RNA-seq data. Hum
Genomics. 8:202014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martins-Neves SR, Corver WE,
Paiva-Oliveira DI, Van den Akker BE, Briaire-de-Bruijn IH, Bovée
JV, Gomes CM and Cleton-Jansen AM: Osteosarcoma stem cells have
active Wnt/β-catenin and overexpress SOX2 and KLF4. J Cell Physiol.
231:876–886. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lonati C, Sordi A, Giuliani D, Spaccapelo
L, Leonardi P, Carlin A, Ottani A, Galantucci M, Grieco P, Catania
A, et al: Molecular changes induced in rat liver by hemorrhage and
effects of melanocortin treatment. Anesthesiology. 116:692–700.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kovacevic A, Hammer A, Stadelmeyer E,
Windischhofer W, Sundl M, Ray A, Schweighofer N, Friedl G,
Windhager R, Sattler W, et al: Expression of serum amyloid A
transcripts in human bone tissues, differentiated osteoblast-like
stem cells and human osteosarcoma cell lines. J Cell Biochem.
103:994–1004. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang Y, Zhao Q, Fan L, Zhang Z, Tan B,
Liu Y and Li Y: Down-regulation of microRNA-381 promotes cell
proliferation and invasion in colon cancer through up-regulation of
LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
